{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:05:14Z","timestamp":1791389114209,"version":"4.3.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01GM1908A"],"award-info":[{"award-number":["01GM1908A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01GM2208"],"award-info":[{"award-number":["01GM2208"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and objectives<\/jats:title>\n            <jats:p>Corticosteroids or plasma exchange are recommended for acute treatment of autoimmune encephalitis (AE). Intravenous immunoglobulins (IVIG) are suggested as an additional treatment option but data on treatment effect is scarce. The objective of the present study was to investigate the impact of the first-line treatment on the three most common forms of AE, in particular, to evaluate the effect of IVIG therapy in these diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 1274 patients from the German Network for Autoimmune Encephalitis Research (GENERATE) were analyzed, and 388 patients were included in the study because they had either anti-NMDAR, anti-LGI1 or anti-CASPR2 antibodies and firs-line immunotherapy (ivMP monotherapy, ivMP\u2009+\u2009IVIG, ivMP\u2009+\u2009PE or ivMP\u2009+\u2009IVIG\u2009+\u2009PE) or no immunotherapy at all. For the statistical analyses, patients were stratified according to antibody type, distinguishing between anti-NMDAR (IgG1) and anti-LGI1 as well as anti-CASPR2 (predominantly IgG4). The primary endpoint was the clinical outcome at discharge, which was assessed using the modified Rankin Scale (mRS). The mRS scores were then compared between the different treatment groups over time, and the factors influencing the reduction in mRS at discharge were analyzed. Furthermore, a specific investigation was conducted to determine the differences in outcomes between patients treated with ivMP\u2009+\u2009IVIG and ivMP\u2009+\u2009PE, each split by antibody subtype.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In all treatment groups analyzed, significant improvements were observed at the time of discharge and after 12\u00a0months compared to disease onset, regardless of the type of first-line treatment. In untreated patients a significant improvement was not observed. The choice of IVIG or PE as an additional treatment to ivMP for anti-NMDAR encephalitis did not affect the primary outcome. In anti-LGI1 or anti-CASPR2 encephalitis, no influence on the primary outcome was observed when IVIG or PE was administered in addition to ivMP, too. However, a direct comparison of the individual antibody subgroups\u2019 mRS reductions, depending on the treatment approach (ivMP\u2009+\u2009IVIG vs. ivMP\u2009+\u2009PE), revealed that a more significant mRS reduction was observed with ivMP\u2009+\u2009PE in anti-NMDAR encephalitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>The retrospective data give evidence that there is no difference in outcome for the use of ivMP\u2009+\u2009PE over ivMP\u2009+\u2009IVIG or vice versa in the treatment of encephalitis caused by antibodies against NMDAR, LGI1 or CASPR2. Furthermore, the specific method of plasma exchange, whether plasmapheresis or immunoadsorption, did not affect the mRS at discharge.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-025-13032-0","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:59:16Z","timestamp":1743159556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2"],"prefix":"10.1007","volume":"272","author":[{"given":"Joyce Christin","family":"Rittel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominica","family":"Hudasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Doppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian Then","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen B.","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rostasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel A.","family":"Friese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Malter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Madlener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lewerenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makbule","family":"Senel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Geis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"Wandinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Leypoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Pr\u00fcss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-481X","authenticated-orcid":false,"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"German Network for Research on Autoimmune Encephalitis (GENERATE)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"23","key":"13032_CR1","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1212\/WNL.0000000000003414","volume":"87","author":"J Dalmau","year":"2016","unstructured":"Dalmau J (2016) NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 cotzias lecture. Neurology 87(23):2471\u20132482","journal-title":"Neurology"},{"issue":"1","key":"13032_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17925\/ENR.2013.08.01.31","volume":"8","author":"F Leypoldt","year":"2013","unstructured":"Leypoldt F, Wandinger KP, Bien CG, Dalmau J (2013) Autoimmune encephalitis. Eur Neurol Rev 8(1):31\u201337","journal-title":"Eur Neurol Rev"},{"issue":"5","key":"13032_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","volume":"87","author":"A van Sonderen","year":"2016","unstructured":"van Sonderen A, Arino H, Petit-Pedrol M, Leypoldt F, Kortvelyessy P, Wandinger KP et al (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87(5):521\u2013528","journal-title":"Neurology"},{"issue":"4","key":"13032_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391\u2013404","journal-title":"Lancet Neurol"},{"issue":"7","key":"13032_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M et al (2021) Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry 92(7):757\u2013768","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"13032_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jnnp-2021-327302","volume":"93","author":"A Rodriguez","year":"2022","unstructured":"Rodriguez A, Klein CJ, Sechi E, Alden E, Basso MR, Pudumjee S et al (2022) LGI1 antibody encephalitis: acute treatment comparisons and outcome. J Neurol Neurosurg Psychiatry 93(3):309\u2013315","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13032_CR7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z (2018) Adverse effects of immunoglobulin therapy. Front Immunol 9:1299","journal-title":"Front Immunol"},{"issue":"4","key":"13032_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","volume":"6","author":"DJ Hamrock","year":"2006","unstructured":"Hamrock DJ (2006) Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 6(4):535\u2013542","journal-title":"Int Immunopharmacol"},{"issue":"8232","key":"13032_CR9","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d\u2019Apuzzo V, Baumgartner C, Hirt A, Morell A et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1(8232):1228\u20131231","journal-title":"Lancet"},{"issue":"2","key":"13032_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1006\/clin.1996.0059","volume":"79","author":"W Stohl","year":"1996","unstructured":"Stohl W, Elliot JE (1996) In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol 79(2):122\u2013133","journal-title":"Clin Immunol Immunopathol"},{"issue":"12","key":"13032_CR11","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1093\/intimm\/5.12.1559","volume":"5","author":"A Saoudi","year":"1993","unstructured":"Saoudi A, Hurez V, de Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD et al (1993) Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol 5(12):1559\u20131567","journal-title":"Int Immunol"},{"issue":"6","key":"13032_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/ACI.0000000000000116","volume":"14","author":"M Ballow","year":"2014","unstructured":"Ballow M (2014) Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol 14(6):509\u2013515","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"13032_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","volume":"13","author":"JD Lunemann","year":"2016","unstructured":"Lunemann JD, Quast I, Dalakas MC (2016) Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics 13(1):34\u201346","journal-title":"Neurotherapeutics"},{"issue":"8","key":"13032_CR14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMc1214823","volume":"368","author":"EW Gelfand","year":"2013","unstructured":"Gelfand EW (2013) Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 368(8):777","journal-title":"N Engl J Med"},{"issue":"2","key":"13032_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD Lunemann","year":"2015","unstructured":"Lunemann JD, Nimmerjahn F, Dalakas MC (2015) Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy. Nat Rev Neurol 11(2):80\u201389","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"13032_CR16","doi-asserted-by":"publisher","first-page":"205427041879302","DOI":"10.1177\/2054270418793021","volume":"9","author":"JA Kinsella","year":"2018","unstructured":"Kinsella JA, Irani SR, Hollingsworth R, O\u2019Shaughnessy D, Kane P, Foster M et al (2018) Use of intravenous immunoglobulin for the treatment of autoimmune encephalitis: audit of the NHS experience. JRSM Open 9(9):2054270418793021","journal-title":"JRSM Open"},{"issue":"3","key":"13032_CR17","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1212\/WNL.0000000000006783","volume":"92","author":"R Balu","year":"2019","unstructured":"Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ (2019) A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 92(3):e244\u2013e252","journal-title":"Neurology"},{"issue":"23","key":"13032_CR18","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017\u20132023","journal-title":"Neurology"},{"issue":"3","key":"13032_CR19","doi-asserted-by":"publisher","first-page":"103019","DOI":"10.1016\/j.autrev.2021.103019","volume":"21","author":"V Morales-Ruiz","year":"2022","unstructured":"Morales-Ruiz V, Juarez-Vaquera VH, Rosetti-Sciutto M, Sanchez-Munoz F, Adalid-Peralta L (2022) Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis. Autoimmun Rev 21(3):103019","journal-title":"Autoimmun Rev"},{"key":"13032_CR20","doi-asserted-by":"publisher","first-page":"175628642311543","DOI":"10.1177\/17562864231154306","volume":"16","author":"AA Pinto","year":"2023","unstructured":"Pinto AA, De Seze J, Jacob A, Reddel S, Yudina A, Tan K (2023) Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review. Ther Adv Neurol Disord 16:17562864231154306","journal-title":"Ther Adv Neurol Disord"},{"key":"13032_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109058","volume":"241","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huan X, Jiao K, Jiang Q, Goh LY, Shi J et al (2022) Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study. Clin Immunol 241:109058","journal-title":"Clin Immunol"},{"issue":"2","key":"13032_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","volume":"14","author":"JF Liu","year":"2010","unstructured":"Liu JF, Wang WX, Xue J, Zhao CB, You HZ, Lu JH et al (2010) Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial 14(2):153\u2013160","journal-title":"Ther Apher Dial"},{"key":"13032_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001116","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC (2022) IgG4-mediated neurologic autoimmunities: understanding the pathogenicity of IgG4, ineffectiveness of IVIg, and long-lasting benefits of anti-B cell therapies. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001116","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"13032_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ana.25421","volume":"85","author":"JA Lim","year":"2019","unstructured":"Lim JA, Lee ST, Moon J, Jun JS, Kim TJ, Shin YW et al (2019) Development of the clinical assessment scale in autoimmune encephalitis. Ann Neurol 85(3):352\u2013358","journal-title":"Ann Neurol"},{"key":"13032_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.796965","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Tu E, Yao C, Liu J, Lei Q, Lu W (2021) Validation of the clinical assessment scale in autoimmune encephalitis in chinese patients. Front Immunol 12:796965","journal-title":"Front Immunol"},{"issue":"6","key":"13032_CR26","doi-asserted-by":"publisher","first-page":"e1088","DOI":"10.1212\/NXI.0000000000001088","volume":"8","author":"FS Thaler","year":"2021","unstructured":"Thaler FS, Zimmermann L, Kammermeier S, Strippel C, Ringelstein M, Kraft A et al (2021) Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry. Neurol Neuroimmunol Neuroinflamm 8(6):e1088","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"13032_CR27","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1111\/epi.17327","volume":"63","author":"A Halliday","year":"2022","unstructured":"Halliday A, Duncan A, Cheung M, Boston RC, Apiwattanakul M, Camacho X et al (2022) Second-line immunotherapy and functional outcomes in autoimmune encephalitis: a systematic review and individual patient data meta-analysis. Epilepsia 63(9):2214\u20132224","journal-title":"Epilepsia"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13032-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13032-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13032-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T10:09:33Z","timestamp":1744970973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13032-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["13032"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13032-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare. MS is employee of Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All aspects of the study have been conducted in accordance with the declaration of Helsinki.Ethical review and approval were not required for the study on human participants according to local legislation and institutional requirements. The patient himself or a legal guardian of the patient gave written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"287"}}